Recently, a dual‐target CAR‐T cell therapy that targets both GPC3 and PD‐1 has been developed, demonstrating the ability to eliminate PD‐L1‐positive HCC tumor cells and modulate the immunosuppressive tumor microenvironment, thereby exhibiting enhanced tumor inhibition compared with single‐target CAR‐T cells [568]. Here, GPC3 is linked to neoplasm.